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Prolonged Jaundice in Newborn
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Abstract
Prolonged jaundice is defined as a serum bilirubin level higher than 85 μmol/L 
(5 mg/dl), which persists at postnatal 14 days in term infants and 21 days following 
the birth in preterm infants. It affects 2–15% of all newborns and 40% of breastfed 
infants. Although underlying cause can not be found in the majority of prolonged 
jaundice cases, this may also be the first sign of a serious causative pathology. Tests 
performed to determine the underlying cause and failure to determine the etiol-
ogy cause anxiety for both families and physicians. The most important point is to 
determine whether prolonged jaundice is of a benign cause or is due to a substantial 
disease. For this reason, health care providers should not take unnecessary tests 
in normal infants, but should also recognize infants with a causative pathology. 
Neonatal jaundice still maintains its importance in neonatal clinical practice, since 
early diagnosis and treatment is feasible.
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1. Introduction
Prolonged jaundice is defined as a serum bilirubin level higher than 85 μmol/L 
(5 mg/dl), which persists at postnatal 14 days in term infants and 21 days following 
the birth in preterm infants. It affects 2–15% of all newborns and 40% of breastfed 
infants [1].
Although underlying cause can not be found in the majority of prolonged 
jaundice cases, this may also be the first sign of a serious causative pathology [2]. 
The most important point is to determine whether prolonged jaundice is of a benign 
cause or is due to a substantial disease. For this reason, health care providers should 
not take unnecessary tests in normal infants, but should also recognize infants with 
a causative pathology. The timing of initial investigations should be between two 
and four weeks in order to reduce the associated mortality and morbidity. Neonatal 
jaundice still maintains its importance in neonatal clinical practice, since early 
diagnosis and treatment is feasible [3–6].
Although jaundice in early infancy is predominantly caused by indirect hyperbili-
rubinemia, it can also be seen as direct hyperbilirubinemia. Distinguishing between 
these types of jaundice is crucial in determining the etiology of prolonged jaundice.
To date, the most common cause of prolonged jaundice of indirect hyperbili-
rubinemia has been identified as breastmilk jaundice. It is known that breastmilk 
jaundice is seen at a rate of 1.3% in newborn infants and 2.4–25% in infants fed with 
breastmilk [7–9]. Besides, breastmilk jaundice may extend up to the twelfth week of 
life [10]. However, the diagnosis of breast milk jaundice is made by excluding other 
causes. Other possible causes of indirect hyperbilirubinemia include dehydration, 
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hemolysis, infection, congenital hypothyroidism, inborn diseases of metabolism, and 
pyloric stenosis [2, 11]. Delayed diagnosis of these causes may increase morbidity.
Despite the jaundiced appearance, newborns with breast milk jaundice appear 
healthy, grow up in a normal way, and have no signs of an underlying disease. 
However, the presence of abnormalities in laboratory tests consistent with hepa-
tobiliary dysfunction, such as elevation of aminotransferases and/or γ-glutamyl 
transpeptidase (GGT), warrants investigating pathological causes [12].
Direct hyperbilirubinemia is defined as serum direct bilirubin >20 μmol/L 
(>1.2 mg/dl) or direct bilirubin >20% of total bilirubin. Although rare, it usually 
indicates an underlying pathological cause and requires immediate investigation 
and prompt intervention. Direct hyperbilirubinemia (cholestatic jaundice) is never 
physiological. It affects 1/2500 live births and should be suspected in all jaundiced 
infants with light coloured stools and/or dark urine [4]. Delayed presentation of 
cholestatic newborns is still an important issue. For the early diagnosis of cho-
lestasis, it is recommended to measure the serum total bilirubin (STB) and direct 
bilirubin levels of each newborn with prolonged jaundice [13].
Intrahepatic or extrahepatic biliary obstructions, viral infections, inborn 
diseases of meatabolism and endocrine disorders can lead to hyperbilirubinemia 
[13]. Extrahepatic biliary atresia is rare. It has been reported to occur at a rate of 1 
per 21,000 live births in the UK and 9 per 14,000 live births in New Zealand [14]. 
Biliary atresia is the most common cause of neonatal cholestasis, and affected 
infants may appear healthy for a considerable time [15]. Kasai hepatoportoen-
terostomy should be performed in the first 45 days of life to restore bile flow and 
reduce further damage to the liver [16]. Early diagnosis of biliary atresia is the most 
important predictive factor in operated newborns [17].
Various conditions such as intrauterine infections, bacterial sepsis, galactose-
mia, aminoacidemias, and congenital hypopituitarism can occur with a mixture of 
increased direct and indirect bilirubin [18].
When severe jaundice goes untreated for too long, it can cause a condition 
called kernicterus. Kernicterus, or bilirubin encephalopathy, is bilirubin-induced 
neurologic damage, typically in infants. It can cause athetoid cerebral palsy and 
hearing loss. Kernicterus also causes problems with vision and teeth and sometimes 
can cause intellectual disabilities. Early detection and management of jaundice can 
prevent kernicterus.
2. Diagnosis
A global protocol for investigating prolonged jaundice is not defined yet. The 
incidence of conditions that play a role in prolonged jaundice in terms of etiology 
varies between countries. This difference is the main reason for the various proto-
cols. The cost of the examinations in cases with prolonged jaundice and the differ-
ences in healthcare systems between countries also contribute to this situation. The 
fact that prolonged jaundice can persist up to 3 months in most of the breastfed 
newborns and that prolonged jaundice in some newborns can be caused by serious 
underlying pathologies, even which may lead to liver transplantation, makes the 
current situation more difficult [19, 20].
The cause of prolonged jaundice seen in 15–40% of newborns is breastfeeding 
[21]. Breast milk jaundice is highly prevalent among the etiologies of prolonged 
jaundice. However, the diagnosis of breast milk jaundice is a diagnosis of exclu-
sion. In neonatal prolonged jaundice, at the first step, direct hyperbilirubinemia 
and indirect hyperbilirubinemia should be differentiated, promptly. This requires 
3
Prolonged Jaundice in Newborn
DOI: http://dx.doi.org/10.5772/intechopen.99670
getting a detailed history of the patient and a meticulous physical examination. 
Especially in the history, stool color and urine color should be questioned. Whether 
the urine and stool color is normal, the following initial tests should be performed.
2.1 Initial tests in patients with prolonged jaundice
If there is no direct bilirubin elevation in the initial tests, these tests are sufficient 
for the follow-up and treatment of neonatal prolonged jaundice [22]. However, 
if increased direct bilirubin level is observed, the infant should be examined for 
cholestasis and specific tests to some cholestatic liver diseases should be done [23].
These examinations are;
3. Etiology
Albeit most of the causes of prolonged jaundice other than breast milk are 
rare, congenital hypothyroidism and direct hyperbilirubinemia, which require 
urgent diagnosis (recognition) and treatment, should also be excluded [6]. 
Determining whether jaundice is hemolytic is important in order to identify the 
initial approach [2]. The causes of indirect hyperbilirubinemia and direct hyper-
bilirubinemia regarding etiological investigation in neonatal prolonged jaundice 
are classified as follows:
Causes of direct hyperbilirubinemia in neonatal prolonged jaundice [24]:
Tests for cholestatic liver disease
1. ALT, AST, ALP, GGT, PT, APTT 6. Serology for TORCH-S infections
2.Abdominal and hepatobiliary ultrasonography 7. Reducing substance in the urine
3. Urine organic acids and blood amino acids 8. Alpha feto protein
4. Serum bile acids 9. Sweat test
5. Alpha-1 antitrypsin level
1. Direct and indirect bilirubin level and liver function tests, 
in case of direct bilirubin level is increased
4. Glucose 6 phosphate dehydrogenase 
(G6PD) enzyme level
2. Complete blood count, peripheral blood smear 5. TSH, fT4
3. Maternal blood group, infant blood group, Direct Coombs 
test




• Neonatal hepatitis syndromes,
• Choledochal cyst,
• Galactosemia
• Alpha-1 antitrypsin deficiency
• Hereditary bile acid synthesis disorders.
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Causes of indirect hyperbilirubinemia in neonatal prolonged jaundice [24]:
3.1 Hemolytic diseases
The reason for isoimmunization in the mother and the formation of IgG anti-
bodies is the passage of fetal erythrocytes into the maternal circulation. The basis 
of hemolytic disease in the newborn is the breakdown of fetal erythrocytes by 
antibodies passing through the placenta [25, 26].
Hemolytic diseases are classified in two groups as immune and nonimmune. 
Rh, ABO and minor blood group incompatibilities are in the immune group. In the 
nonimmune hemolytic group, erythrocyte enzyme defects, erythrocyte structural 
defects, infection, polycythemia and sequestration exist. Rh and ABO incompat-
ibilities are the most common causes of immune hemolytic diseases [27, 28].
3.1.1 Rhesus incompatibility
Rh incompatibility occurs in 30–35% of cases of prolonged jaundice which goes 
with hemolysis [29, 30]. Rh is a large protein with many antigenic sites. Common 
antigens are D, C, c, and E antigens. All antigens cause their specific antibody 
responses. In fact, 90% of this response is against the D antigen [31]. Therefore, a 
response to the D antigen is required for the diagnosis of Rh positivity [32]. Since 
the Rh antigen is only present on the erythrocyte membrane, severe hemolysis 
can be met in the event of Rh compability [33]. Rh system genes are located in the 
short arm of chromosome 1. The presence of the Rh gene can be learned in the 
first trimester by polymerase chain reaction (PCR) method via amniocentesis. 
Alloimmunization occurs when as little as 0.1 ml of blood from the Rh (D) positive 
fetus passes through the placenta into the circulation of the Rh negative mother [28, 
30, 34]. The level of antibodies developed in the mother determines the degree of 
hemolytic disease. Hemolysis is caused by IgG type antibodies. The level of these 
antibodies indicates that the mother is sensitized.
In order to prevent the risk of Rh hemolytic disease and maternal sensitization, 
Rh (−) women whose spouses are Rh (+) should be routinely administered 300 μg 
anti-D immunoglobulin (Rhogam), whether the indirect Coombs test result is (−) 
at 28 weeks of pregnancy. This dose provides a prophylaxis for Rhesus disease in 
the vast majority of deliveries. The risk increases gradually in pregnancies after 
maternal sensitization [35]. The increase in serum bilirubin level during follow-up 
determines the severity of the hemolytic event [36].
Prolonged jaundice can be seen in Rh incompatibility. Rh incompatibility 
should not be forgotten in patients with prolonged jaundice which goes with 
hemolysis.




• Urinary tract infection
• Extravascular blood collection
• Pyloric stenosis
• Gilbert syndrome
• Crigler najjar syndrome
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3.1.2 ABO incompatibility
The most common blood group incompatibility is the ABO group incompat-
ibility. It does not cause serious problems generally, although it is the most com-
mon reason. Unlike Rh incompatibility, the mother does not need to be sensitized 
beforehand in this entity [37]. Hemolytic disease due to ABO incompatibility is seen 
in cases where the mother’s blood type is O and the infant has A or B blood type. 
Although ABO incompatibility is seen in 20–25% of pregnancies, fetal sensitization 
findings (direct Coombs positivity) vary between 3 and 4% [38, 39].
Unlike Rh incompatibility, most of the maternal antibodies for ABO incompat-
ibility are in the IgM form. Therefore, those antibodies do not have the ability of 
crossing the placenta. In addition, A and B antigens are not only found on erythro-
cytes, they are also found on different tissue cells. Consequently, not all antibodies 
passed to the fetus are retained by erythrocytes, but by other tissue cell antigens 
as well. These situations described, are the main reasons why ABO incompatibility 
does not cause serious problems compared to Rh incompatibility [40].
The clinical course resulting from hemolysis due to ABO incompatibility is 
generally mild in many cases and jaundice is observed as the only clinical find-
ing. Jaundice usually develops on the first day and is often kept under control 
with phototherapy [38]. However, severe hemolysis due to ABO incompatibility is 
considerably rare [41].
Since it is the most common condition in patients with prolonged jaundice with 
hemolysis, it should definitely be investigated.
3.1.3 Subgroup incompatibility
Minor blood group incompatibility accounts for as low as 3% of neonatal hemo-
lytic disease cases. Duffy, Kidd and MNS antigens are responsible for this hemoly-
sis. The pathophysiology of hemolysis is similar to Rh and ABO incompatibilities. 
Minor blood group incompatibilities can usually cause subclinical hemolysis as well 
as possible severe hemolysis and worsen pictures [30, 34].
Since it usually goes with subclinical hemolysis, it may cause milder manifesta-
tions such as prolonged jaundice [42].
3.1.4 Erythrocyte enzyme deficiencies
The most common enzyme defects are; Glucose 6 phosphate dehydrogenase 
deficiency is a deficiency of 5′ nucleotidase and pyruvate kinase.
3.1.5 Glucose 6 phosphate dehydrogenase deficiency (G6PD)
The most common enzyme deficiency is glucose 6 phosphate dehydrogenase 
deficiency. The G6PD enzyme acts as a catalyst and helps to reduce oxidative 
products in erythrocytes.
Due to the X-linked recessive inheritance, it is more common in male. Numerous 
mutations of the G6PD gene have been detected on the X chromosome. Because of 
having so many variants of the enzyme, hemolysis caused by G6PD can be pres-
ent in different scenarios [43, 44]. In infants with G6PD in the neonatal period, 
hemolysis develops in case of exposure to oxidant stress or infection, and jaundice 
occurs as a result. Jaundice usually develops within 24–72 hours of life. In newborns 
with G6PD enzyme deficiency, bilirubin conjugation is much lower than in infants 
with normal G6PD enzyme. In fact, there are newborns with kernicterus caused 
by G6PD deficiency in the literatüre [45, 46]. The rate of G6PD deficiency in the 
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etiology of prolonged jaundice varies according to populations. Various studies 
reported the rate of G6PD deficiency between 3.8% and 24% [47, 48].
Since prolonged jaundice may be the first sign of G6PD deficiency, the enzyme 
level should be checked in newborns diagnosed with prolonged jaundice.
3.1.6 Pyruvate kinase enzyme deficiency
It is inherited autosomal recessively. It is less common than G6PD deficiency. 
Unlike G6PD deficiency, signs of hyperbilirubinemia, anemia and reticulocytosis 
are present from the very beginning. Pyruvate kinase enzyme deficiency should be 
considered in infants with negative Coombs test and hemolytic anemia, in case of 
prolonged jaundice without erythrocyte membrane defect [49].
3.1.7 Erythrocyte membrane defects
Hereditary spherocytosis, eliptocytosis, stomatocytosis and infantile pycnocy-
tosis, which are erythrocyte membrane defects, can elicit hemolysis in the neonatal 
period. Hereditary spherocytosis is common in this group, while hereditary elliptocy-
tosis and stomatocytosis are the other rare causes of hemolysis in newborn infants.
3.1.7.1 Hereditary spherocytosis
It has an autosomal dominant inheritance. Transforming spherocytic erythro-
cytes, which are more fragile than normal ones, under osmotic stress, is the char-
acteristic of hereditary spherocytosis. The diagnosis of hereditary spherocytosis is 
made by detecting spherocytes in the peripheral smear and by osmotic fragility test. 
ABO incompability can be confused with hemolytic disease. Because microsphero-
cytes can also be seen in the peripheral blood smear in ABO hemolytic disease. The 
distinction between these two diseases is made with the direct Coombs test [49].
Kocabay et al. found the rate of hereditary spherocytosis to be 0.1% in neonatal 
jaundice cases. Hyperbilirubinemia occurs in approximately half of newborn 
infants with hereditary spherocytosis, but this jaundice is usually considered as 
physiological, and may be overlooked. It can also be a reason for prolonged jaundice 
in a minority of the newborn infants [50].
3.2 Bilirubin uptake and conjugation disorders of the liver
3.2.1 Gilbert’s syndrome
In Gilbert’s syndrome, both hepatocytes’ bilirubin uptake is decreased and 
UDPGT activity is decreased. It is inherited in autosomal dominant or autosomal 
recessive. It has a prevalence of 2–6%. Although it can cause neonatal hyperbili-
rubinemia, the diagnosis is usually made at a later stage [25, 50]. It is thought that 
hyperbilirubinemia, which is observed in newborns with weight loss after insuf-
ficient caloric intake, also has a similar etiologic mechanism to Gilbert’s syndrome. 
Phenobarbital can be used as treatment in selected cases of Gilbert’s syndrome [51].
Studies have shown that Gilbert syndrome either elicit neonatal prolonged jaundice.
3.2.2 Crigler Najjar syndrome type 1
Crigler-Najjar Syndrome type 1 is caused by the complete absence of the hepatic 
glucuronyl transferase enzyme and is inherited autosomal recessively. It is a chronic 
non-hemolytic indirect hyperbilirubinemia syndrome and has a severe clinical 
7
Prolonged Jaundice in Newborn
DOI: http://dx.doi.org/10.5772/intechopen.99670
course. In the homozygous form, severe indirect hyperbilirubinemia, which may 
progress to kernicterus, develops within the first three days of life, and bilirubin 
levels increase gradually, whether treatment is delayed. Diagnosis is made by per-
cutaneous liver biopsy. UGT activity is measured in the biopsy sample/specimen. 
Phenobarbital is not an effective treatment of choice in Crigler-Najjar Syndrome 
type 1 syndrome [43, 52].
3.2.3 Crigler Najjar Syndrome type 2
Crigler Najjar Syndrome Type 2 is more common than Type 1. Besides, the clini-
cal course is better. The reason for this is that the activity of the UDPGT enzyme 
is partially present in Type 2. It has an autosomal dominant inheritance. Although 
indirect bilirubin levels start to increase in the first days of life, they usually do 
not go above 20 mg/dl levels. Unlike type 1, Crigler-Najjar Syndrome responds to 
phenobarbital. Therefore, response to phenobarbital can be used as a distinguishing 
strategy for type 1 and type 2 disease [25, 53]. Crigler-Najjar syndrome is also an 
important reason for prolonged jaundice.
In Crigler-Najjar syndrome type II, UDPGT activity is reduced in the same way as 
is found in infants with prolonged jaundice due to Gilbert’s syndrome [54]. Therefore, 
it is an etiology that should be kept in mind in newborns with prolonged jaundice.
3.2.4 Lucey Driscoll Syndrome
It is a rare disease of newborn, which goes with high bilirubin levels in the 
postnatal first two days of life. Bilirubin levels are above 20 mg/dl and may rise to 
levels that can require exchange transfusion. These high bilirubin levels can persist 
for longer than 14 days [40]. Most of these infants develop kernicterus, whether 
exchange transfusion is not performed.
3.3 Hypothyroidism
It is one of the substantial causes of neonatal prolonged jaundice. Prolonged 
jaundice is seen in approximately 10% of infants with congenital hypothyroidism. 
Decreased UGT activity is blamed for the pathophysiology of hyperbilirubinemia seen 
in congenital hypothyroidism. In this case, hyperbilirubinemia may persist for several 
months. Treatment with thyroid hormone leads rapid resolution of jaundice [55, 56].
3.4 Galactosemia
Galactosemia may present with hyperbilirubinemia in the neonatal period. In 
the clinical picture of the disease; there are findings such as vomiting, dehydration, 
hepatomegaly, splenomegaly. Diagnosis is made by detecting the reducing sub-
stance in urine, sugar chromatography and enzyme levels [30].
Galactosemia is one of the etiologies of prolonged conjugated hyperbiliru-
binemia as a hereditary and metabolic disease. In newborns with galactosemia, 
hyperbilirubinemia becomes evident in the first week of life and can proceed with 
prolonged jaundice in many patients [57].
3.5 Infections
In the neonatal period, infections can be accompanied by jaundice. Particularly, 
urinary tract infections, and sepsis are common causes of jaundice. Indirect hyper-
bilirubinemia can develop in sepsis due to hemolysis caused by endotoxins [44].
Neonatal Intensive Care Unit
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Direct and indirect hyperbilirubinemia is seen in congenital infections such as 
TORCH-S group infections [30].
The incidence of urinary tract infection in asymptomatic infants, under 
two months of age with jaundice, but without fever, has been shown to be 7.5%. 
Therefore, prolonged jaundice may be the unique finding in urinary tract infection 
[58]. In a study, the most common infection associated with jaundice in the neonatal 
period was found to be urinary tract infection [59].
3.6 Extravascular blood collection
Extravasation of blood in the body leads to increased bilirubin production by 
enhanced heme protein metabolism via destruction of erythrocytes. Accumulation 
of red blood cells in tissue layers surrounding the brain and skull (cephalo hema-
toma, subdural hematoma, subgaleal hematoma) or in any part of the body in 
traumatic deliveries can lead severe hyperbilirubinemia [60].
3.6.1 Cephal hematoma
Cephal hematoma defines a bleeding into the subperiosteal region and occurs in 
approximately 1–2% of all live births. Rupture of vessels results in a blood collection 
extending from the bone to the periosteum during labor [61]. Cephal hematoma 
can be causitive for jaundice due to the increase in bilirubin synthesis in the first 
48–72 hours of life because of the destruction of erythrocytes in the extravasous 
blood collection [41].
4. Treatment of neonatal jaundice
The aim of the treatment is to reduce the increased bilirubin levels in order to 
prevent the damage to the central nervous system by the formation of kernicterus. 
Timely and prompt treatment is crucial to prevent the permanent effects of biliru-
bin toxicity such as kernicterus [62].
Whether the underlying cause of hyperbilirubinemia is known, treatment 
should be arranged according to that etiology. The most commonly used methods in 
the treatment of jaundice are: Phototherapy, intra venous immunoglobulin (IVIG) 
administration, exchange transfusion, and phenobarbital. Treatment indications 
vary according to the gestational week of the infant, postnatal age, bilirubin level, 
and the presence of hemolysis [63].
It is appropriate to use the curves designed by American Academy of Pediatrics, 
which evaluate either the gestational week, and risk factors for infants whose gesta-
tional age is greater than 35 weeks. Instead, the tables include the cut-off bilirubin 
levels according to birth weight, for the infants whose gestational age is less than 
35 weeks [64].
In case of a rapid rise in bilirubin levels within the first 24 hours, newborn infants 
should be evaluated for hemolysis. The ETCOc measurement directly indicates heme 
Treatment of Neonatal Jaundice
1. Phototherapy 2. Phenobarbital
3. Intravenous Immunoglobulin 4. Metalloporphyrins
5. Exchange Transfusion
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catabolism and bilirubin production [65]. The hourly rate of increase in bilirubin 
levels is also an important indicator for hemolysis. An increase of 0.2–0.5 mg/dl per 
hour in the bilirubin level is thought as an indicator of hemolysis. With a positive 
direct Coombs test (+), higher reticulocyte count, a decrease in hemoglobin and 
hematocrit levels are laboratory findings supporting hemolysis [66].
4.1 Phototherapy
Phototherapy is used to reduce increased serum bilirubin level and reach a 
normal bilirubin level, to reduce the need for exchange transfusion and to prevent 
the development of kernicterus. Phototherapy lowers bilirubin levels by using 
certain wavelengths of light energy [67]. Blue light at a wavelength of 440–460 nm 
is the value at which bilirubin is best absorbed. In order for phototherapy to be 
effective, the energy must be a maximum of 5u/cm/nm. In order to obtain this 
energy, ideally, 440–460 nm, which is the best absorbed wavelength, and blue 
light should be used. The distance of the light should be adjusted to be 30–40 cm 
away from the infant. It should be given at the ideal wavelength and distance of 40 
uw/cm/nm [68, 69]. In the same way, multidirectional administration of one-way 
phototherapy, from different angles enhances the success of the treatment [70].
In phototherapy, treatment decision was determined by bilirubin level, rate of 
increase in bilirubin level over time, birth weight, gestational age and postnatal age, 
and the presence of risk factors such as Rh, ABO and minor blood group incompat-
ibility, G6PD enzyme deficiency, presence of asphyxia, hypothermia, acidosis, 
sepsis, and lower levels of albumin. Phototherapy is started when the serum 
bilirubin rises to a level that pose a risk for neurotoxicity. Phototherapy should 
be started in bilirubin values that exceed the determined limits. Risk factors that 
should be considered when determining the phototherapy limit are: Rh, ABO and 
minor blood group incompatibility, G6PD, albumin levels below 3 g/dl, presence of 
asphyxia, pronounced tendency to sleep, sepsis, hypothermia, presence of acidosis 
in blood gas analysis. In order for a newborn to be considered risk-free, all risk fac-
tors must be excluded, otherwise the newborn is considered as under risk. Decision 
of phototherapy, depends on the TSB.
Phototherapy is considered as safe. But it can have some undesirable effects. 
These side effects can be listed as follows: Retinal degeneration without an eye 
protective cover, fluid loss, bronze baby syndrome, rash, lactose intolerance, hypo-
calcemia, an increased risk of PDA particularly in preterm infants [40, 68]. There 
are studies showing that phototherapy increases the risk of conjunctivitis, and it 
predisposes to asthma and allergic rhinitis in long term [71].
4.2 Exchange transfusion
Exchange transfusion is a successful but risky treatment method used in severe 
neonatal hyperbilirubinemia [72]. When TSB exceeds the cut-off level that is deter-
mined for exchange transfusion, the procedure should be performed without a delay.
Whether the expected decrease is not reached in TSB level despite intensive 
phototherapy or in case of a gradual increase, or when the risk of kernicterus is 
greater than the risk of exchange transfusion, or whether kernicterus has developed 
and signs are present, transfusion should be performed quickly [73].
When albumin levels are low, more care should be taken in terms of exchange 
transfusion. Because the amount of free bilirubin that cannot be bound to albumin 
will increase and there will be a high amount of free bilirubin which can increase 
the risk of kernicterus. The bilirubin/albumin ratio does not make a decision for 
exchange transfusion, but is used to support the treatment decision in conjunction 
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with TSB levels in newborn infants. Albumin infusion is not recommended in 
patients with either hyperbilirubinemia and hypoalbuminemia [66].
A central catheter is placed before the patient for blood exchange. Then, blood 
collection from the newborn and replacement of the patient’s own blood with 
whole blood or erythrocyte suspension mixed with plasma are performed through 
this catheter. Approximately twice of the blood volume of the infant, which cor-
responds to 160–170 ml/kg, is exchanged by this way. The volume of blood taken 
or given once during the exchange transfusion process should not exceed 5 ml/kg. 
Besides, the volume rate of blood given or taken in the exchange process should 
not be more than 2 mL/kg/min. The reason for this is that if this rate is exceeded, 
sudden changes in intracranial pressure can occur due to blood pressure fluctuation 
[74]. The exchange transfusion process ensures that the majority of the infant’s 
sensitized erythrocytes are replaced by unsensitized erythrocytes. This change 
provides a significant decrease in serum bilirubin level.
Serum electrolytes, bilirubin and blood glucose level should be checked at regular 
intervals during exchange transfusion. Because hypocalcemia and hypoglycemia may 
occur depending on the content of the blood product used during the procedure.
Exchange transfusion is not an innocent procedure and complications may 
befall. During the procedure, the newborn can have apnea, blood pressure imbal-
ances can be met, the heart rate can slow down, electrolyte disturbances may be 
observed, disturbances in blood glucose level can be observed, thrombocytopenia, 
coagulation disorders, disseminated intravascular coagulation, metabolic acidosis, 
thromboembolism, malnutrition, necrotizing enterocolitis, sepsis can also be 
observed. While the risk of death is 1% in healthy infants, it is 12% in infants with 
risk factors [75].
The use of exchange transfusion has greatly decreased due to the frequent and 
ideal use of phototherapy. This has also reduced the incidence of possible mortality 
and morbidity risk arising from the exchange transfusion procedure.
4.3 Pharmacological treatment
Agents used to treat neonatal jaundice can be classified according to their 
action of mechanism as follows; Inhibition of bilirubin (Tin protoporphyrin and 
mesoporphyrin, Zinc protoporphyrin and mesoporphyrin), accelerating biliru-
bin excretion process (Phenobarbital, Ethanol, Chloroquine, Antihistamines, 
Clofibrate, Antipyrine), inhibiting the enterohepatic circulation (Agar, Activated 
charcoal, Cholestyrylpyrron, bilirubin oxidase) and IVIG [75]. IVIG, pheno-
barbital, and metalloporphyrins are the most preferred ones in the treatment of 
hyperbilirubinemia.
4.3.1 Phenobarbital
Phenobarbital is a potent inducer of microsomal enzymes. It makes this strong 
induction by inducing the enzyme glucuronyl transferase. By this mechanism, it 
increases bilirubin conjugation, excretion and bile flow, which means that it affects 
all steps of bilirubin metabolism. In addition, phenobarbital is used in the diagnosis 
and treatment of Crigler Najjar disease [76]. It is recommended for use only in high-
risk conditions.
4.3.2 Intravenous immunoglobulin
Intravenous immunoglobulin therapy can be used in Coombs test positive Rh 
or ABO incompatibility, minor blood group incompatibility, and newborn infants 
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who received intrauterine transfusion/s. IVIG should be given timely at a dose of 
0.5–1 g/kg and within 2 hours, without delay, in newborn infants with hyperbili-
rubinemia that do not decrease despite intense phototherapy, and whose bilirubin 
level is close to the limits of exchange transfusion [77].
High-dose IVIG therapy in newborn infants, such as a dose of 0.5 g/kg, reduces 
the need for exchange transfusion. It does this by slowing the rate of bilirubin rise 
and lowering maximum bilirubin levels. IVIG is thought to prevent hemolysis by its 
mechanism of blocking reticuloendothelial Fc receptors [78, 79].
As a special case, the management of hemolytic disease due to Rh incompatibil-
ity is as follows; Preparation should be made before birth. First of all, preparation 
of the blood product to be given should be done. Since exchange transfusion can 
be required as soon as in the delivery room, equipment should be ready for use 
and IVIG should be kept, if needed. A staff experienced in neonatal resuscitation 
should be present. As soon as the infant is born; intensive phototherapy treatment 
is started and IVIG is given to the patient as a pharmacological treatment promptly. 
Hemoglobin (Hb) and STB levels are checked from the blood sample taken from 
the umbilical cord. Intensive phototherapy should be started in newborn infants 
born above 38 weeks, if the bilirubin level is above 6 mg/dL and/or the Hb value is 
less than 10 g/dL in the blood sample taken from the umbilical cord, as well as the 
preparation begins for exchange transfusion. In case of the STB increase is more 
than 0.5 mg/dL per hour despite intensive phototherapy and IVIG therapy, rapid 
exchange transfusion should be performed [80].
4.3.3 Metalloporphyrins
Metalloporphyrins, which competitively inhibit heme oxygenase enzyme, slow 
down bilirubin synthesis. The most effective metalloporphyrin is Tin (Sn) because 
it lowers bilirubin [81, 82]. A single dose of 6 μmol/kg is used in the treatment of 
neonatal jaundice. It has been observed that Sn-mesoporphyrin applied together 
with phototherapy can elicit transient erythema in some of the newborn infants. 
Currently, metalloporphyrins are not a part of routine practice of treatment for 
neonatal jaundice [76].
5. Conclusion
Prolonged jaundice can become an intensive care problem, if not noticed early. 
Extreme hyperbilirubinemia (TB of 25 to 30 mg/dL) can cause bilirubin encepha-
lopathy, Kernicterus, which is usually characterized by the deposition of unconju-
gated bilirubin in brain cells. Neuronal necrosis/damage occurs in the basal ganglia, 
hippocampus, hypothalamic nuclei as a bilirubin-phosphatidylcholine precipitate, 
diencephalon, midbrain, neurohumoral and electrolyte control, brainstem nuclei 
for oculomotor and auditory function, and in the cerebellum. Clinical manifesta-
tions include cerebral palsy, deafness, seizures, etc.
Neonatal Intensive Care Unit
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